雄激素受体在乳腺癌中的表达及其预后意义

发布时间：2018-06-16 23:41

本文选题：乳腺肿瘤 + 受体　；参考：《上海交通大学学报(医学版)》2017年05期

【摘要】：目的·探讨雄激素受体(AR)在乳腺癌中的表达情况及其预后意义。方法·选取2013年10月-2016年12月就诊于上海交通大学医学院附属瑞金医院、仁济医院及苏州九龙医院的183例女性乳腺癌患者,采用免疫组织化学检测肿瘤组织中AR蛋白的表达,分析AR表达与临床病理特征的相关性;采用在线生存分析数据库(Kmplot)观察AR基因的表达与乳腺癌患者预后的相关性。结果·AR蛋白的阳性率为47.5%。AR阳性者具有相对较低的组织学分级[57.6%(G1/G2)vs 25.0%(G3),P0.05]。在雌激素受体、孕激素受体及P53阳性者中,AR蛋白的阳性率高于阴性组(P0.05)。分子分型为管腔型者AR蛋白的阳性率高于表皮生长因子受体-2过表达及三阴性乳腺癌组(51.7%vs 31.6%,P0.05)。单因素分析结果显示,AR基因阳性的乳腺癌患者的无复发生存、总生存、无远处转移生存明显高于AR阴性者(P0.05)。结论·乳腺癌中AR阳性患者的预后较好,AR通路抑制剂可能成为治疗AR阳性乳腺癌的选择。
[Abstract]:Objective to investigate the expression of androgen receptor ARA in breast cancer and its prognostic significance. Methods from October 2013 to December 2016, 183 women with breast cancer were selected from Ruijin Hospital, Renji Hospital and Suzhou Jiulong Hospital, Shanghai Jiaotong University Medical College. The expression of AR protein was detected by immunohistochemistry. The correlation between AR expression and clinicopathological features was analyzed, and the correlation between AR gene expression and prognosis of breast cancer patients was observed by online survival analysis database (Kmplot). Results the positive rate of AR protein was 47.5%. The positive rate of AR protein was relatively low [57.6G ~ (1 / G _ (2) vs 25.0% G _ (3) P _ (0.05). The positive rate of AR protein in estrogen receptor, progesterone receptor and p53 positive group was higher than that in negative group. The positive rate of AR protein was higher than that of epidermal growth factor receptor-2 overexpression and triple negative breast cancer. Univariate analysis showed that the survival of breast cancer patients with positive AR gene was significantly higher than that of patients with AR negative. Conclusion AR pathway inhibitor may be the choice of AR positive breast cancer in patients with AR positive breast cancer.
【作者单位】：上海交通大学医学院附属瑞金医院病理科;上海交通大学医学院附属苏州九龙医院肿瘤科;上海交通大学医学院附属仁济医院肿瘤科;
【基金】：国家自然科学基金(81301858) 苏州科技计划项目(SYS201308,SYS201404)~~
【分类号】：R737.9

【相似文献】